ALNY
NASDAQAlnylam Pharmaceuticals Inc.
Price$292.07-28.40 (-8.86%)
2026-03-052026-06-08
News · 26 weeks83+100%
2025-12-142026-06-07
Mix3690d
- Insider15(42%)
- Other11(31%)
- SEC Filings6(17%)
- Analyst2(6%)
- Earnings2(6%)
Latest news
25 items- PRAlnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics− Collaboration is valued at up to $2B with upfront consideration of $30M − − Alliance pairs Alnylam's RNAi platform and 20+ years of proprietary data with Inceptive's foundation models and AI expertise to catalyze progress beyond rational drug design – − Partnership designed to accelerate timelines and unlock innovative oligonucleotide designs − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, and Inceptive Nucleics, Inc., which builds foundation models of life, today announced a strategic collaboration agreement to increase the pace of therapeutic innovation. The collaboration is valued at up to $2B with upfront consideration of $30M, including cas
- INSIDERDirector Pyott David E I sold $1,145,853 worth of shares (3,830 units at $299.18) as part of a pre-agreed trading plan and converted options into 3,830 shares (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERSEC Form 4 filed by Director Cravatt Benjamin4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cravatt Benjamin3 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- SECSEC Form 144 filed by Alnylam Pharmaceuticals Inc.144 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
- PRAnti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain MomentumUSA News Group News CommentaryIssued on behalf of Avaí Bio, Inc.As the broader cell and gene therapy complex posts record quarterly revenue and advances toward accelerated approval pathways, a Nevada-based longevity joint venture has just cleared a manufacturing-stage gate on its α-Klotho anti-aging program.NEW YORK, May 28, 2026 /CNW/ -- Cell and gene therapy has crossed a meaningful inflection in 2026. Vertex Pharmaceuticals reported Q1 product revenue of $2.99 billion, with newer non-CF franchises CASGEVY and JOURNAVX contributing more than 25% of year-over-year growth. Alnylam Pharmaceuticals delivered its first-ever $1 billion product revenue quarter. Beam Therapeutics presented updated
- SECAlnylam Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
- INSIDERDirector Sigal Charles Elliott was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Schulman Amy W was granted 838 shares, increasing direct ownership by 4% to 24,049 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Reitan Colleen F was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Pyott David E I was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Kellogg Peter N was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Hamburg Margaret A was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Brandicourt Olivier was granted 671 shares, increasing direct ownership by 87% to 1,446 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Ausiello Dennis A was granted 671 shares, increasing direct ownership by 74% to 1,582 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- INSIDERDirector Arbuckle Stuart A was granted 671 shares (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- PRAlnylam Issues 2025 Corporate Responsibility Report– Published Scope 1 and Scope 2 Greenhouse Gas (GHG) Emissions Reduction Framework through 2030 – – Expanded Global Patient Access and Support – Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced the publication of its 2025 Corporate Responsibility Report. The 2025 report details how the company is scaling its corporate responsibility efforts in tandem with its business growth. Reflected throughout the report is the global theme, "Accepting Challenges to Improve the Health of Humanity," which remains central to Alnylam's strategy and is embedded across six interconnected pillars that guide the company's work: Patients, Science, Employees,
- ANALYSTCitigroup initiated coverage on Alnylam Pharma with a new price targetCitigroup initiated coverage of Alnylam Pharma with a rating of Buy and set a new price target of $380.00
- INSIDERDirector Schulman Amy W exercised 11,250 shares at a strike of $70.20, increasing direct ownership by 94% to 23,211 units (SEC Form 4)4 - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Issuer)
- PRNew Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden− Reductions in All-Cause Mortality and Recurrent Cardiovascular Events Maintained Across Key Patient Subgroups, Including Patients Taking a Broad Range of Heart Failure Therapies – − Pooled Analysis of Over 25,000 Patient-Years of Experience with TTR-Silencing RNAi Therapies Shows a Consistent Safety Profile, Including No Clinically Meaningful Ocular Effects of Vitamin A Lowering – − DemonsTTRate Study Designed to Generate Long-Term Real-World Evidence in More Than 2,000 Patients with ATTR-CM − Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopat
- PRAlnylam to Webcast Presentations at Upcoming Investor ConferencesAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las Vegas, Nevada Goldman Sachs Annual Healthcare Conference on Tuesday, June 9, 2026, at 11:20 am ET in Miami, Florida. A live audio webcast of each presentation will be available on the Investors section of the Company's website, www.alnylam.com/events. Replays will be available on the Alnylam website within 48 hours after each event. About Alnylam Pharmaceuticals Alnylam (NASDAQ:ALNY) is
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Alnylam Pharmaceuticals Inc.SCHEDULE 13G/A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Subject)
- PRAlnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CMAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients w
- SECSEC Form 10-Q filed by Alnylam Pharmaceuticals Inc.10-Q - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
- SECAlnylam Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)
ALNY FAQ
7 questionsWhat does Alnylam Pharmaceuticals Inc. do?
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP)...Where does ALNY stock trade?
Alnylam Pharmaceuticals Inc. (ALNY) is listed on NASDAQ.What sector and industry is ALNY in?
Alnylam Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Alnylam Pharmaceuticals Inc. go public?
Alnylam Pharmaceuticals Inc. (ALNY) completed its IPO in 2004.What are analysts saying about ALNY?
Alnylam Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2026-05-19.What companies are similar to ALNY?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALNY side-by-side with any of them on Quantisnow.How can I track ALNY on Quantisnow?
Quantisnow aggregates Alnylam Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALNY to receive live email and push alerts on every new disclosure.